RU2007121812A

RU2007121812A - METHOD FOR LOCAL IMMUNOTHERAPY OF PURULENT INFLAMMATORY DISEASES OF SOFT TISSUES OF ORGANO-FACIAL REGION

Info

Publication number: RU2007121812A
Application number: RU2007121812/14A
Authority: RU
Inventors: Лариса Сергеевна Латюшина (RU); Лариса Сергеевна Латюшина; Илья Ильич Долгушин (RU); Илья Ильич Долгушин
Priority date: 2007-06-09
Filing date: 2007-06-09
Publication date: 2008-12-20
Also published as: RU2361607C2

Abstract

Способ локальной иммунотерапии гнойно-воспалительных заболеваний мягких тканей челюстно-лицевой области, включающий введение иммуномодулятора с учетом фаз гнойного раневого процесса на фоне комплексного медикаментозного лечения, отличающийся тем, что в качестве иммунопрепарата применяют ронколейкин в виде раствора с дозой активного вещества 0,5 мг или 500000 ME, который в экссудативно-воспалительную фазу гнойного раневого процесса вводят в рану на турундах, разведенным либо 0,9%-ным раствором хлорида натрия, либо 10%-ным гипертоническим раствором хлорида натрия (при выраженной экссудации), при этом на периферию гнойной раны накладывают повязку с 20%-ным раствором димексида, проводя ежедневные перевязки, а в пролиферативную фазу сочетают орошение раны раствором ронколейкина с дозой активного вещества 500000 ME, разведенного 0,9%-ным раствором хлорида натрия и мазевые повязки водорастворимыми формами, проводя перевязки через день.The method of local immunotherapy of purulent-inflammatory diseases of the soft tissues of the maxillofacial region, including the introduction of an immunomodulator taking into account the phases of the purulent wound process against the background of complex drug treatment, characterized in that roncoleukin is used as an immunologic drug in the form of a solution with a dose of the active substance of 0.5 mg or 500,000 ME, which is introduced into the wound in the exudative-inflammatory phase of the purulent wound process in turunds diluted with either 0.9% sodium chloride solution or 10% hypertonic race a thief of sodium chloride (with severe exudation), while a dressing is applied to the periphery of the purulent wound with a 20% solution of dimexide, daily dressings are performed, and irrigation of the wound with a roncoleukin solution with a dose of 500,000 IU diluted with 0.9% is combined in the proliferative phase solution of sodium chloride and ointment dressings with water-soluble forms, conducting dressings every other day.

Claims

The method of local immunotherapy of purulent-inflammatory diseases of the soft tissues of the maxillofacial region, including the introduction of an immunomodulator taking into account the phases of the purulent wound process against the background of complex drug treatment, characterized in that roncoleukin is used as an immunologic drug in the form of a solution with a dose of the active substance of 0.5 mg or 500,000 ME, which is introduced into the wound in the exudative-inflammatory phase of the purulent wound process in turunds diluted with either 0.9% sodium chloride solution or 10% hypertonic race a thief of sodium chloride (with severe exudation), while a dressing is applied to the periphery of the purulent wound with a 20% solution of dimexide, daily dressings are performed, and irrigation of the wound with a roncoleukin solution with a dose of 500,000 IU diluted with 0.9% is combined in the proliferative phase solution of sodium chloride and ointment dressings with water-soluble forms, conducting dressings every other day.